Has Amanda Piquet, MD received payments from drug or device companies?

Yes. Drug and device makers reported $106,338 in general payments to Amanda Piquet, MD across 139 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Amanda Piquet, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Amanda Piquet, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Amanda Piquet, MD

Neurology · Aurora, CONPI 1447513122

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $90,682 of the $106,338 with a category attached, or 85.3%. 18 manufacturers reported payments, led by AstraZeneca at 57.2% of the total. Reporting peaked in 2024 at $35,053 and has fallen 58.9% since, to $14,421 in 2025. Among neurology clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$106,338in general payments, 2019–2025

Across 139 payments — averaging $765.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$61K
F. Hoffmann-la Roche AG$22K
Amgen$8K
Genentech USA, Inc.$8K
Hoffmann-la Roche Limited$3K
E.r. Squibb & Sons, L.L.C.$2K
plus $2K from 12 others

$1,184,214in research payments, 2019–2025

Across 161 payments — averaging $7355.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Genentech, Inc.$746K
AbbVie$262K
Roche Products Limited$70K
E.r. Squibb & Sons, L.L.C.$59K
UCB SA$23K
Bristol Myers Squibb$23K
plus $1K from 1 others

What the payments were for

Consulting fees$90,68285%
Speaking & faculty fees$2,2502%
Travel & lodging$8,2378%
Food & beverage$5,1095%
Education$610%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	67	$60,854
F. Hoffmann-la Roche AG	21	$22,022
Amgen(2 entities)	15	$8,379
Genentech USA, Inc.	10	$8,317
Hoffmann-la Roche Limited	3	$2,656
E.r. Squibb & Sons, L.L.C.	1	$1,920
UCB SA	1	$720
EMD Serono, Inc.	1	$440
Novartis	3	$263
TG Therapeutics, Inc.	2	$216
Roche Products Limited	2	$211
Bristol Myers Squibb	5	$114
UCB, Inc.	2	$72
AbbVie	1	$43
Neurocrine Biosciences, Inc.	1	$38
Genentech, Inc.	2	$31
Biogen	1	$21
Mylan Specialty L.p.	1	$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

ULTOMIRIS$26,725
SOLIRIS$25,574
OCREVUS$10,715
UPLIZNA$7,972
Enspryng$6,113
Non-Covered Product$1,515
BRIUMVI$141
GILENYA$124

How this compares

$106,338 in reported general payments places this provider in the 90th percentile of 334 neurology providers in Colorado.

See all neurology providers in Colorado →

Medicare billing

Part B allowed, 2024

$25,801

Medicare patients

Services billed

292

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
GammakedImmune Globul G/Gly/Iga Avg 46	16	$438,697
PanzygaImmun Glob G(Igg)-Ifas/Glycine	15	$240,703
Gamunex-CImmune Globul G/Gly/Iga Avg 46	24	$192,308
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50	17	$173,754
XembifyImmune Globulin,gamma(Igg)klhw	21	$69,450
Mycophenolic AcidMycophenolate Sodium	12	$3,563
Baclofen	34	$1,176
Diazepam	19	$1,102
Lacosamide	25	$1,091
Gabapentin	27	$599
Clonazepam	47	$388
Sodium Chloride0.9 % Sodium Chloride	23	$341
Pregabalin	16	$296
Prednisone	14	$150
Ketorolac Tromethamine	18	$137

Paid to pharmacies, not to this prescriber.

Other neurology in Aurora

Jeffrey BennettAurora$605K
Enrique AlvarezAurora$407K
Anna ShahAurora$157K
Timothy VollmerAurora$136K
Simon OhAurora$112K
Brent MorelAurora$79K
Drew KernAurora$68K
Ondrea TimmermannAurora$33K
Thomas RagoleAurora$31K
Maria NagelAurora$27K

See the full list for Colorado →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →